BACKGROUND AND PURPOSE: The safety and efficacy of SBCAS have not been evaluated in detail. The purpose of our study was to evaluate the outcome after SBCAS in high-risk patients compared with unilateral stent placement. MATERIALS AND METHODS: Between March 2002 and October 2008, a total of 205 consecutive high-risk patients underwent CAS at our institution. Of these patients, 30 (14.6%) underwent SBCAS (n = 24) and staged SBCAS (n = 6). Patients who underwent unilateral CAS (n = 175) during the same period served as controls. The stroke risk factors, procedural results, and outcome at 30 days and 6 months, as well as the restenosis rate at 6 months, were compared by using either the chi(2) test or the Kruskal-Wallis equality-of-populations rank test. RESULTS: Our data revealed no significant differences in the stroke risk factors between the SBCAS and the control group. HPS occurred more commonly in SBCAS (ie, 16.7%, 4/24) compared with 2.9% (5/175) in the control group (P = .014). However, there was no statistical significance between 2 groups in the event rate of stroke (minor and/or major stroke), death, or restenosis at 6 months. CONCLUSIONS: There was no significant difference in outcome at 6 months following stent placement between SBCAS and unilateral CAS in the high-risk patient group, even though HPS occurred more commonly after SBCAS.
BACKGROUND AND PURPOSE: The safety and efficacy of SBCAS have not been evaluated in detail. The purpose of our study was to evaluate the outcome after SBCAS in high-risk patients compared with unilateral stent placement. MATERIALS AND METHODS: Between March 2002 and October 2008, a total of 205 consecutive high-risk patients underwent CAS at our institution. Of these patients, 30 (14.6%) underwent SBCAS (n = 24) and staged SBCAS (n = 6). Patients who underwent unilateral CAS (n = 175) during the same period served as controls. The stroke risk factors, procedural results, and outcome at 30 days and 6 months, as well as the restenosis rate at 6 months, were compared by using either the chi(2) test or the Kruskal-Wallis equality-of-populations rank test. RESULTS: Our data revealed no significant differences in the stroke risk factors between the SBCAS and the control group. HPS occurred more commonly in SBCAS (ie, 16.7%, 4/24) compared with 2.9% (5/175) in the control group (P = .014). However, there was no statistical significance between 2 groups in the event rate of stroke (minor and/or major stroke), death, or restenosis at 6 months. CONCLUSIONS: There was no significant difference in outcome at 6 months following stent placement between SBCAS and unilateral CAS in the high-risk patient group, even though HPS occurred more commonly after SBCAS.
Authors: A Mathur; G S Roubin; S S Iyer; C Piamsonboon; M W Liu; C R Gomez; J S Yadav; H D Chastain; L M Fox; L S Dean; J J Vitek Journal: Circulation Date: 1998-04-07 Impact factor: 29.690
Authors: Susan M Trocciola; Rabih A Chaer; Stephanie C Lin; Evan J Ryer; Brian De Rubertis; Nicholas J Morrissey; James McKinsey; K Craig Kent; Peter L Faries Journal: J Vasc Surg Date: 2006-04 Impact factor: 4.268
Authors: Nicolas Diehm; Barry T Katzen; Sriram S Iyer; Christopher J White; L Nelson Hopkins; Lynne Kelley Journal: J Vasc Surg Date: 2008-04-28 Impact factor: 4.268
Authors: Alex Abou-Chebl; Jay S Yadav; Joel P Reginelli; Christopher Bajzer; Deepak Bhatt; Derk W Krieger Journal: J Am Coll Cardiol Date: 2004-05-05 Impact factor: 24.094
Authors: B S Choi; J W Park; J E Shin; P-H Lü; J K Kim; S J Kim; D H Lee; J S Kim; H J Kim; D C Suh Journal: Interv Neuroradiol Date: 2010-10-25 Impact factor: 1.610
Authors: D C Suh; J L Kim; E H Kim; J K Kim; J-H Shin; D H Hyun; H Y Lee; D H Lee; J S Kim Journal: AJNR Am J Neuroradiol Date: 2012-01-19 Impact factor: 3.825
Authors: J H Kwak; L Zhao; J K Kim; S Park; D-G Lee; J H Shim; D H Lee; J S Kim; D C Suh Journal: AJNR Am J Neuroradiol Date: 2013-10-03 Impact factor: 3.825